Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 54c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.55), $0.54 better than the analyst estimate of ($1.09).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Cytek faces $56M damages award in Beckman Coulter patent case
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises